In particular, selective modulation of mGlu2 is a potential strategy for the treatment of schizophrenia 20-22, depression 23, 24, Parkinson's disease (PD) 25-28, Alzheimer's disease (AD) 29, 30, drug abuse and addiction 31-35. Here, GRM2 is linked to major depressive disorder.